Tozinameran (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tozinameran" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

19web.archive.org

1^st place

2^nd place

12nih.gov

4^th place

8^th place

8doi.org

2^nd place

5^th place

3europa.eu

68^th place

28^th place

2who.int

195^th place

64^th place

2reuters.com

49^th place

97^th place

2semanticscholar.org

11^th place

51^st place

2jazmp.si

low place

1,569^th place

2mednet-communities.net

low place

1gov.uk

432^nd place

1,914^th place

1theguardian.com

12^th place

44^th place

1letemps.ch

1,980^th place

9,669^th place

1npr.org

92^nd place

351^st place

1statnews.com

8,771^st place

7,096^th place

1nbcnews.com

137^th place

646^th place

1bbc.com

20^th place

70^th place

1biontech.de

low place

1cvdvaccine-us.com

low place

1nhs.uk

1,989^th place

720^th place

1gatesnotes.com

low place

1degruyter.com

1,425^th place

1,482^nd place

1biospectrumasia.com

low place

1worldcat.org

5^th place

10^th place

1swr.de

1,755^th place

low place

1fosunpharma.com

low place

1bloomberg.com

99^th place

331^st place

1eib.org

7,951^st place

low place

1europeanpharmaceuticalreview.com

low place

bbc.com

Gallagher J (9. november 2020). »Covid vaccine: First 'milestone' vaccine offers 90% protection«. BBC News. Arhivirano iz spletišča dne 26. novembra 2020. Pridobljeno 9. novembra 2020.

biontech.de

investors.biontech.de

»Update on our COVID-19 vaccine development program with BNT162b2« (tiskovna objava). BioNTech. 2. december 2020. Arhivirano iz prvotnega spletišča (PDF) dne 3. decembra 2020. Pridobljeno 12. decembra 2020.

biospectrumasia.com

»CEPI's collaborative task force to assess COVID-19 vaccines on emerging viral strains«. BioSpectrum - Asia Edition. 23. november 2020. the first SARS-CoV-2 viral genomes were shared via GISAID on 10 January 2020{{navedi novice}}: Vzdrževanje CS1: url-status (povezava)

bloomberg.com

»BioNTech gets $445 million in German funding for vaccine«. Bloomberg.com. 15. september 2020. Arhivirano iz spletišča dne 9. novembra 2020. Pridobljeno 10. novembra 2020.

cvdvaccine-us.com

»Questions and Answers About Pfizer-BioNTech COVID-19 Vaccine«. Pfizer. Arhivirano iz prvotnega spletišča dne 24. januarja 2021. Pridobljeno 16. decembra 2020. Arhivirano 2021-01-24 na Wayback Machine.

degruyter.com

Bohn, Mary Kathryn (7. oktober 2020). »IFCC Interim Guidelines on Molecular Testing of SARS-CoV-2 Infection«. Clinical Chemistry and Laboratory Medicine. 58 (12): 1993–2000. doi:10.1515/cclm-2020-1412. PMID 33027042.

doi.org

Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, in sod. (Oktober 2020). »Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates«. The New England Journal of Medicine. 383 (25): 2439–50. doi:10.1056/NEJMoa2027906. PMC 7583697. PMID 33053279.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, in sod. (december 2020). »Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine«. N Engl J Med. 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Polack, Fernando (10. december 2020). »Safety and Efficacy of the mRNA Covid-19 Vaccine«. New England Journal of Medicine. 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246. development of BNT162b2 was initiated on January 10, 2020, when the SARS-CoV-2 genetic sequence was released by the Chinese Center for Disease Control and Prevention and disseminated globally by the GISAID (Global Initiative on Sharing All Influenza Data) initiative
Bohn, Mary Kathryn (7. oktober 2020). »IFCC Interim Guidelines on Molecular Testing of SARS-CoV-2 Infection«. Clinical Chemistry and Laboratory Medicine. 58 (12): 1993–2000. doi:10.1515/cclm-2020-1412. PMID 33027042.
Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, in sod. (9. april 2020). »The COVID-19 vaccine development landscape«. Nature Reviews Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591.
Fauci AS, Lane HC, Redfield RR (Marec 2020). »Covid-19: Navigating the uncharted«. The New England Journal of Medicine. 382 (13): 1268–69. doi:10.1056/nejme2002387. PMC 7121221. PMID 32109011.
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, in sod. (Oktober 2020). »Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults«. Nature. 586 (7830): 589–593. doi:10.1038/s41586-020-2639-4. PMID 32785213. S2CID 221126922.
Gaebler C, Nussenzweig MC (Oktober 2020). »All eyes on a hurdle race for a SARS-CoV-2 vaccine«. Nature. 586 (7830): 501–502. doi:10.1038/d41586-020-02926-w. PMID 33077943. S2CID 224808629.

eib.org

»Germany: Investment Plan for Europe – EIB to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing«. European Investment Bank. 11. junij 2020. Arhivirano iz spletišča dne 9. novembra 2020. Pridobljeno 10. novembra 2020.

europa.eu

ema.europa.eu

https://www.ema.europa.eu/en/documents/overview/comirnaty-epar-medicine-overview_sl.pdf, Evropska agencija za zdravila, EMA, Comirnaty (cepivo proti covidu-19 na osnovi mRNA [s spremenjenimi nukleozidi]), Pregled cepiva Comirnaty in zakaj je odobreno v EU; vpogled: 8. 1. 2020.
https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_sl.pdf Povzetek glavnih značilnosti zdravila Comirnaty, vpogled: 10. 1. 2021.
»EMA Assessment Report« (PDF). www.ema.europa.eu. 21. december 2020. Pridobljeno 29. decembra 2020.{{navedi splet}}: Vzdrževanje CS1: url-status (povezava)

europeanpharmaceuticalreview.com

Hannah B (7. oktober 2020). »EMA begins rolling review of BNT162b2 COVID-19 vaccine«. European Pharmaceutical Review. Arhivirano iz spletišča dne 11. novembra 2020. Pridobljeno 11. novembra 2020.

fosunpharma.com

《Fosun Pharma and BioNTech form COVID-19 vaccine strategic alliance in China Arhivirano 2020-06-14 na Wayback Machine.》（Fosun Phrama News Content , 15. 3. 2020）

gatesnotes.com

Gates B (30. april 2020). »The vaccine race explained: What you need to know about the COVID-19 vaccine«. The Gates Notes. Arhivirano iz spletišča dne 14. maja 2020. Pridobljeno 2. maja 2020.

gov.uk

»UK medicines regulator gives approval for first UK COVID-19 vaccine« (tiskovna objava). Medicines and Healthcare products Regulatory Agency (MHRA). 2. december 2020. Pridobljeno 2. decembra 2020.

jazmp.si

https://www.jazmp.si/2020/12/21/comirnaty-mrna-cepivo-proti-covid-19-s-spremenjenimi-nukleozidi/ JAZMP, COMIRNATY – mRNA cepivo proti covid-19 (s spremenjenimi nukleozidi), 21. decembra 2020, vpogled: 10. januarja 20221.
https://www.jazmp.si/2021/03/11/ema-objavila-zakljucke-drugega-mesecnega-porocila-o-varnosti-cepiva-comirnaty-pfizer-biontech-in-prvega-za-cepivo-covid-19-moderna/, vpogled: 16. 3. 2021.

letemps.ch

»Swissmedic autorise un premier vaccin contre le coronavirus« (v francoščini). Le Temps. 19. december 2020. Pridobljeno 19. decembra 2020.

mednet-communities.net

World Health Organization. »INN: Tozinameran«. WHO MedNet. Arhivirano iz prvotnega spletišča dne 9. marca 2021. Pridobljeno 1. decembra 2020. Arhivirano 2021-03-09 na Wayback Machine.
World Health Organization. »Messenger RNA encoding the full-length SARS-CoV-2 spike glycoprotein«. WHO MedNet. Arhivirano iz prvotnega spletišča (DOC) dne 5. januarja 2021. Pridobljeno 16. decembra 2020. Arhivirano 2021-01-05 na Wayback Machine.

nbcnews.com

Edwards E (9. november 2020). »Pfizer's Covid-19 vaccine promising, but many questions remain«. NBC News. Arhivirano iz spletišča dne 22. novembra 2020. Pridobljeno 12. novembra 2020.

nhs.uk

»Coronavirus vaccine«. National Health Service. 7. december 2020. Arhivirano iz spletišča dne 7. decembra 2020. Pridobljeno 7. decembra 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, in sod. (Oktober 2020). »Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates«. The New England Journal of Medicine. 383 (25): 2439–50. doi:10.1056/NEJMoa2027906. PMC 7583697. PMID 33053279.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, in sod. (december 2020). »Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine«. N Engl J Med. 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Polack, Fernando (10. december 2020). »Safety and Efficacy of the mRNA Covid-19 Vaccine«. New England Journal of Medicine. 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246. development of BNT162b2 was initiated on January 10, 2020, when the SARS-CoV-2 genetic sequence was released by the Chinese Center for Disease Control and Prevention and disseminated globally by the GISAID (Global Initiative on Sharing All Influenza Data) initiative
Bohn, Mary Kathryn (7. oktober 2020). »IFCC Interim Guidelines on Molecular Testing of SARS-CoV-2 Infection«. Clinical Chemistry and Laboratory Medicine. 58 (12): 1993–2000. doi:10.1515/cclm-2020-1412. PMID 33027042.
Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, in sod. (9. april 2020). »The COVID-19 vaccine development landscape«. Nature Reviews Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591.
Fauci AS, Lane HC, Redfield RR (Marec 2020). »Covid-19: Navigating the uncharted«. The New England Journal of Medicine. 382 (13): 1268–69. doi:10.1056/nejme2002387. PMC 7121221. PMID 32109011.
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, in sod. (Oktober 2020). »Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults«. Nature. 586 (7830): 589–593. doi:10.1038/s41586-020-2639-4. PMID 32785213. S2CID 221126922.
Gaebler C, Nussenzweig MC (Oktober 2020). »All eyes on a hurdle race for a SARS-CoV-2 vaccine«. Nature. 586 (7830): 501–502. doi:10.1038/d41586-020-02926-w. PMID 33077943. S2CID 224808629.

ncbi.nlm.nih.gov

Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, in sod. (Oktober 2020). »Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates«. The New England Journal of Medicine. 383 (25): 2439–50. doi:10.1056/NEJMoa2027906. PMC 7583697. PMID 33053279.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, in sod. (december 2020). »Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine«. N Engl J Med. 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Polack, Fernando (10. december 2020). »Safety and Efficacy of the mRNA Covid-19 Vaccine«. New England Journal of Medicine. 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246. development of BNT162b2 was initiated on January 10, 2020, when the SARS-CoV-2 genetic sequence was released by the Chinese Center for Disease Control and Prevention and disseminated globally by the GISAID (Global Initiative on Sharing All Influenza Data) initiative
Fauci AS, Lane HC, Redfield RR (Marec 2020). »Covid-19: Navigating the uncharted«. The New England Journal of Medicine. 382 (13): 1268–69. doi:10.1056/nejme2002387. PMC 7121221. PMID 32109011.

npr.org

Palca J (9. november 2020). »Pfizer says experimental COVID-19 vaccine is more than 90% effective«. NPR. Arhivirano iz spletišča dne 9. novembra 2020. Pridobljeno 9. novembra 2020.

reuters.com

Burger L (15. marec 2020). »BioNTech in China alliance with Fosun over coronavirus vaccine candidate«. Reuters. Arhivirano iz spletišča dne 14. novembra 2020. Pridobljeno 10. novembra 2020.
»China's Fosun to end BioNTech's COVID-19 vaccine trial, seek approval for another«. Reuters. 3. november 2020. Arhivirano iz spletišča dne 12. decembra 2020. Pridobljeno 21. novembra 2020.

semanticscholar.org

api.semanticscholar.org

Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, in sod. (Oktober 2020). »Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults«. Nature. 586 (7830): 589–593. doi:10.1038/s41586-020-2639-4. PMID 32785213. S2CID 221126922.
Gaebler C, Nussenzweig MC (Oktober 2020). »All eyes on a hurdle race for a SARS-CoV-2 vaccine«. Nature. 586 (7830): 501–502. doi:10.1038/d41586-020-02926-w. PMID 33077943. S2CID 224808629.

statnews.com

Herper M (9. november 2020). »Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate«. STAT. Arhivirano iz spletišča dne 9. novembra 2020. Pridobljeno 9. novembra 2020.

swr.de

Papadopoulos C (14. december 2020). »Chronologie - So entstand der Corona-Impfstoff von Biontech« [Chronology - That's how the Covid-vaccine of Biontech was being developed] (v nemščini). Südwestrundfunk. Arhivirano iz prvotnega spletišča dne 2. decembra 2020. Pridobljeno 20. decembra 2020. Arhivirano 2020-12-02 na Wayback Machine.

theguardian.com

Boseley S, Halliday J (2. december 2020). »UK approves Pfizer/BioNTech Covid vaccine for rollout next week«. The Guardian. Pridobljeno 14. decembra 2020.

web.archive.org

World Health Organization (2020). »International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 124 – COVID-19 (special edition)« (PDF). WHO Drug Information. 34 (3): 666. Arhivirano (PDF) iz spletišča dne 27. novembra 2020. Pridobljeno 23. novembra 2020.
Palca J (9. november 2020). »Pfizer says experimental COVID-19 vaccine is more than 90% effective«. NPR. Arhivirano iz spletišča dne 9. novembra 2020. Pridobljeno 9. novembra 2020.
Herper M (9. november 2020). »Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate«. STAT. Arhivirano iz spletišča dne 9. novembra 2020. Pridobljeno 9. novembra 2020.
Edwards E (9. november 2020). »Pfizer's Covid-19 vaccine promising, but many questions remain«. NBC News. Arhivirano iz spletišča dne 22. novembra 2020. Pridobljeno 12. novembra 2020.
Gallagher J (9. november 2020). »Covid vaccine: First 'milestone' vaccine offers 90% protection«. BBC News. Arhivirano iz spletišča dne 26. novembra 2020. Pridobljeno 9. novembra 2020.
»Update on our COVID-19 vaccine development program with BNT162b2« (tiskovna objava). BioNTech. 2. december 2020. Arhivirano iz prvotnega spletišča (PDF) dne 3. decembra 2020. Pridobljeno 12. decembra 2020.
»Questions and Answers About Pfizer-BioNTech COVID-19 Vaccine«. Pfizer. Arhivirano iz prvotnega spletišča dne 24. januarja 2021. Pridobljeno 16. decembra 2020. Arhivirano 2021-01-24 na Wayback Machine.
»Coronavirus vaccine«. National Health Service. 7. december 2020. Arhivirano iz spletišča dne 7. decembra 2020. Pridobljeno 7. decembra 2020.
Gates B (30. april 2020). »The vaccine race explained: What you need to know about the COVID-19 vaccine«. The Gates Notes. Arhivirano iz spletišča dne 14. maja 2020. Pridobljeno 2. maja 2020.
»World Health Organization timeline – COVID-19«. Svetvna zdravstvena organizacija. 27. april 2020. Arhivirano iz spletišča dne 29. aprila 2020. Pridobljeno 2. maja 2020.
Papadopoulos C (14. december 2020). »Chronologie - So entstand der Corona-Impfstoff von Biontech« [Chronology - That's how the Covid-vaccine of Biontech was being developed] (v nemščini). Südwestrundfunk. Arhivirano iz prvotnega spletišča dne 2. decembra 2020. Pridobljeno 20. decembra 2020. Arhivirano 2020-12-02 na Wayback Machine.
Burger L (15. marec 2020). »BioNTech in China alliance with Fosun over coronavirus vaccine candidate«. Reuters. Arhivirano iz spletišča dne 14. novembra 2020. Pridobljeno 10. novembra 2020.
《Fosun Pharma and BioNTech form COVID-19 vaccine strategic alliance in China Arhivirano 2020-06-14 na Wayback Machine.》（Fosun Phrama News Content , 15. 3. 2020）
»BioNTech gets $445 million in German funding for vaccine«. Bloomberg.com. 15. september 2020. Arhivirano iz spletišča dne 9. novembra 2020. Pridobljeno 10. novembra 2020.
»Germany: Investment Plan for Europe – EIB to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing«. European Investment Bank. 11. junij 2020. Arhivirano iz spletišča dne 9. novembra 2020. Pridobljeno 10. novembra 2020.
Hannah B (7. oktober 2020). »EMA begins rolling review of BNT162b2 COVID-19 vaccine«. European Pharmaceutical Review. Arhivirano iz spletišča dne 11. novembra 2020. Pridobljeno 11. novembra 2020.
»China's Fosun to end BioNTech's COVID-19 vaccine trial, seek approval for another«. Reuters. 3. november 2020. Arhivirano iz spletišča dne 12. decembra 2020. Pridobljeno 21. novembra 2020.
World Health Organization. »INN: Tozinameran«. WHO MedNet. Arhivirano iz prvotnega spletišča dne 9. marca 2021. Pridobljeno 1. decembra 2020. Arhivirano 2021-03-09 na Wayback Machine.
World Health Organization. »Messenger RNA encoding the full-length SARS-CoV-2 spike glycoprotein«. WHO MedNet. Arhivirano iz prvotnega spletišča (DOC) dne 5. januarja 2021. Pridobljeno 16. decembra 2020. Arhivirano 2021-01-05 na Wayback Machine.

who.int

World Health Organization (2020). »International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 124 – COVID-19 (special edition)« (PDF). WHO Drug Information. 34 (3): 666. Arhivirano (PDF) iz spletišča dne 27. novembra 2020. Pridobljeno 23. novembra 2020.
»World Health Organization timeline – COVID-19«. Svetvna zdravstvena organizacija. 27. april 2020. Arhivirano iz spletišča dne 29. aprila 2020. Pridobljeno 2. maja 2020.

worldcat.org

Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, in sod. (9. april 2020). »The COVID-19 vaccine development landscape«. Nature Reviews Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591.